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Intravitreal Triamcinolone Acetonide Injection for Macular
Edema Due to Central Retinal Vein Occlusion Persisting
Despite Multiple Intravitreal Bevacizumab Injections
Rayan A. Alshareef, Sunir J. Garg, Jason Hsu, James Vander, Carl Park, and Marc J. Spirn
Abstract
Purpose: To evaluate the response to intravitreal triamcinolone acetonide for macular edema persisting or
recurring despite multiple intravitreal bevacizumab (IVB) treatments for central retinal vein occlusion (CRVO).
Methods: Retrospective interventional case series of 21 eyes with CRVO from 21 patients who were diagnosed
with persistent or recurrent macular edema secondary to CRVO and treated with 0.1mL (4mg) intravitreal
triamcinolone acetonide (IVTA) after initial treatment with 3 or more IVB injections. Anatomic and visual
responses were the study primary outcomes.
Results: Mean logarithm of the minimum angle of resolution visual acuity was 1.19 (20/316) immediately
before IVTA injection, and improved to 1.04 (20/219) 1 month after IVTA administration (P= 0.003). The
mean central macular thickness on optical coherence tomography decreased from 533.4mm immediately before
IVTA to 327.9mm after IVTA injection (P < 0.001). No cases of endophthalmitis, retinal detachment, or
neovascularization were noted.
Conclusions: Intravitreal triamcinolone acetonide appears to improve vision and reduce persistent or recurrent
macular edema secondary to CRVO despite multiple bevacizumab injections.
Introduction
Central retinal vein occlusion (CRVO) remains amajor cause of significant visual morbidity due to reti-
nal hemorrhage, macular ischemia, neovascular glaucoma, and
macular edema.1 Although a number of therapeutic modalities
have been used to treat CRVO-associated macular edema, in-
traocular injection ofmedications, most commonly intravitreal
steroids (i.e., intravitreal triamcinolone acetonide [IVTA] and
dexamethasone implant) and antivascular endothelial growth
factor (VEGF) agents (i.e., pegaptanib, bevacizumab, ranibi-
zumab, and aflibercept), are the most extensively studied and
commonly used classes of mediations. VEGF is upregulated
in patients with ischemic retinopathy, including CRVO.2,3
Both steroids and anti-VEGF agents reduce VEGF concen-
trations although through different mechanisms of action.4,5
The 2011 American Society of Retina Specialists’ Pre-
ferences and Trends survey reported that many clinicians
use anti-VEGF agents as first-line therapy for the treatment
of CRVO, partly due to efficacy and partly due to reduced
cataract formation and a lower incidence of increased in-
traocular pressure compared with intraocular steroids.6
Several studies found visual benefits as well as reduction
of macular edema from repeated use of intravitreal bevac-
izumab (IVB, Avastin; Genentech, Inc., South San Fran-
cisco, CA).7 More recently, a prospective randomized study
of patients with CRVO-related macular edema found that
between 46.2% and 47.7% of patients gain greater than or
equal to 15 letters from baseline with monthly ranibizumab
(Lucentis; Genentech, Inc.) compared with 16.9% of sham
controls.8 Despite these encouraging results, 15% of patients
treated with ranibizumab had no visual gain and 12% of
patients actually lost vision despite therapy.
The dexamethasone implant (OZURDEX; Allergan,
Inc.) and IVTA are considered the most commonly used
intravitreal steroids. The dexamethasone implant is a potent
corticosteroid that is approved by the United States Food
and Drug Administration following results of 2 identical,
randomized, prospective, multicenter, masked, sham-controlled,
parallel group, phase 3 clinical trials that demonstrated sig-
nificant therapeutic benefits compared with sham treat-
ment for macular edema associated with BRVO or CRVO.9
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Triamcinolone acetonide is a corticosteroid that has been
shown to improve vision and decrease macular edema in
eyes with retinal vein occlusion.10,11 A randomized, sham-
controlled clinical trial demonstrated that for macular edema
associated with CRVO, IVTA resulted in a significant im-
provement in both visual acuity as well as a decrease in
macular edema.12,13 Despite a previous study with a small
sample size that assessed the change in visual acuity and
macular edema in patients with nonischemic CRVO who
were previously unresponsive to IVB and who received
IVTA, little is known about the efficacy of triamcinolone
acetonide or the dexamethasone implant when administered
in the setting of macular edema persisting or recurring fol-
lowing the administration of bevacizumab.14
Persistent or recurrent macular edema following anti-
VEGF therapy can be defined as a lack of retinal thickness
reduction and/or a lack of improved visual acuity after re-
peated and continued dosing of anti-VEGF therapy.
Because the mechanisms of action of triamcinolone and
anti-VEGF agents differ, some patients who do not respond
adequately to anti-VEGF therapy may respond well to in-
traocular triamcinolone. We sought to evaluate whether pa-
tients with persistent macular edema due to a CRVO despite
IVB injections respond to subsequent IVTA injection.
Methods
We retrospectively reviewed the charts of all patients ini-
tially treated with IVB for macular edema secondary to
CRVO who subsequently received IVTA (Kenalog-40;
Bristol-Myers Squibb, Princeton, NJ). The study protocol was
approved by the Wills Eye Institute institutional review board
and was conducted in accordance with the Declaration of
Helsinki and all study patients signed a consent form before
each injection. The following data were collected: age, gen-
der, Snellen visual acuity measures at each visit, number,
timing and type of intravitreal injections, assessment of pre-
treatment fluorescein angiography to determine the type of
CRVO, optical coherence tomography (OCT) evaluation for
central retinal thickness, and any adverse events. Patients
were included if they received intravitreal triamcinolone
acetonide for persistent or recurrent macular edema second-
ary to CRVO after at least 3 previous IVB injections. Ex-
clusion criteria included less than 4 weeks of follow up after
IVTA injection, previous focal or panretinal laser photoco-
agulation treatment, previous ranibizumab injection, and
systemic steroid use. Changes in central macular thickness
(CMT) and Snellen visual acuity were the primary endpoints.
Throughout the study period, all patients were scheduled
for visits at 4- to 5-week intervals. Patient assessment and
treatment was done within 5 days of the scheduled visit.
Retreatment criteria included persistent or recurrent macular
edema on clinical examination and/or vision loss. OCT was
performed at the discretion of the treating physician. Rea-
sons behind switching to IVTA included bevacizumab failure
(persistent or recurrent macular edema and/or worsening vi-
sion), patient preference (to try an available alternative treat-
ment method), and treating physician preference (perceived
suboptimal response to IVB).
The 2 OCT machines used in this study were the Stratus
OCT, a time domain OCT instrument, and the Cirrus HD-
OCT a spectral domain OCT instrument (both commercially
available from Carl Zeiss Meditec, Inc., Dublin, CA).
Scanning with the Stratus OCT was performed by using the
fast macular thickness map protocol, which acquires 6
evenly spaced 6-mm radial lines, consisting of 128 A-scans
per line, intersecting at the fovea. Scanning with the Cirrus
HD-OCT was performed with the macular cube 512· 128
scan protocol where a 6· 6-mm area on the retina is scanned
with 128 horizontal lines, each consisting of 512 A-scans
per line. CMT was obtained from the center subfield of the
macular thickness map.
Statistical analyses were performed using Microsoft Ex-
cel (Microsoft Corporation, Redmond, WA). A 2-tailed
student’s t-test was used to compare visual acuity and OCT
thickness results following both bevacizumab and triam-
cinolone acetonide treatments. The visual acuity measure-
ments were converted to logarithm of the minimum angle of
resolution (logMAR) units to facilitate statistical analysis.
Results
A total of 21 patients met the inclusion and exclusion
criteria. There were a total of 12 males (57%) and 9 females
(42.8%), with a mean age of 66.4 years (range 38–82 years).
All patients had fluorescein angiography performed at the
time of diagnosis. Nine eyes had ischemic CRVO, and 12
eyes had nonischemic CRVO. Patients received a mean of
4.1 bevacizumab injections (range 3–10) before IVTA in-
jection. Individual patient data can be found in Table 1.
The mean visual acuity at initial diagnosis (before starting
IVB therapy) was 1.21 (Snellen equivalent 20/330, range 20/
70 to counting fingers at 2 feet). Initial bevacizumab treatment
resulted in a mean logMAR visual acuity of 1.19 (Snellen
equivalent 20/316, range 20/70 to counting fingers at 1 feet,
P= 0.90), and mean CMT on OCT was 533.4mm (range 300–
811mm) before triamcinolone acetonide treatment.
On follow-up after triamcinolone injection, the mean
logMAR visual acuity improved to 1.04 (Snellen equiva-
lent was 20/219, range 20/50 to counting fingers at 3 feet,
P= 0.003), and mean macular thickness decreased signifi-
cantly to 327.9 mm (range 233–630mm, P < 0.001). Two
patients did not show a decrease in CMT on OCT following
IVTA, however, visual acuity improved in one of these
patients. The other lost one line of vision compared with
pre-IVTA measurements. On follow-up, 5 eyes received a
second triamcinolone acetonide injection. One month after
retreatment (at 2-month follow-up), all 5 eyes maintained
stable visual acuity and displayed mild anatomic improve-
ment. A subgroup analysis was performed based on the type
of CRVO. Both nonischemic and ischemic eyes had a sta-
tistically significant reduction in CMT on follow-up [non-
ischemic (P = 0.003) and ischemic (P= 0.007)]. Statistical
significant improvement of visual acuity was noted in non-
ischemic eyes (P= 0.014), but not in eyes with ischemic
CRVO (P= 0.062). Patients received a mean of 1.6 IVTA
injections (range 1–4). Mean follow-up following IVTA was
13 weeks (range 12–15).
No significantly adverse events, including endophthalmitis,
elevated intraocular pressure, or cataract formation, were
noted in any patients during the follow-up period.
Discussion
Macular edema due to CRVO occurs due to increased
venous pressure, loss of the integrity of the blood–retinal
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barrier, and damage to the vascular endothelial tight junc-
tion proteins.1 These dysregulations lead to increased VEGF
levels, and increased VEGF expression appears to correlate
with disease severity.2,3 Recently, VEGF inhibitors and
steroids have been developed as a novel mechanism directed
approach to treat macular edema secondary to CRVO.8 Ra-
nibizumab and bevacizumab are monoclonal antibodies that
inhibit all isoforms of VEGF-A; they have been used to treat
several conditions that cause macular edema and retinal is-
chemia.5,7 Results to date have been favorable and both ra-
nibizumab and the off-label use of bevacizumab have resulted
in improved visual acuity in several large clinical trials and
case series.7,8,15–18 Although many patients have decreased
macular edema and improved visual acuity with ongoing
therapy, a significant number of patients have persistent
macular edema despite anti-VEGF therapy.
The reasons for a persistent macular edema may be pa-
tient related or therapy regimen related. Patient-related
factors include tachyphylaxis to the drug, drug resistance,
increased rate of drug clearance, macular ischemia, or me-
chanical resistance such as a taut posterior hyaloid or an
epiretinal membrane.19,20 Regimen-related reasons include
treatment given too infrequently or stopped prematurely.
Whereas anti-VEGF therapy reduces VEGF levels, pro-
cesses such as dysregulation of endothelial tight junction
proteins and the presence of inflammatory cytokines may
persist resulting in persistent macular edema.21,22
Corticosteroids help mitigate many of the processes that
contribute to the development of macular edema. The mode
of action of triamcinolone acetonide not only downregulates
VEGF expression but also decreases vascular permeability,
stabilizes endothelial and retinal pigment epithelium tight
junctions, decreases major histocompatibility class II expres-
sion, suppresses inflammatory cells, and inhibits the synthesis
of cytokines and leukocyte movement.23,24 This retrospec-
tive study was performed to examine the effect of triam-
cinolone acetonide on macular edema refractory to multiple
bevacizumab injections and highlights a method to decrease
macular edema that persists despite multiple IVB treat-
ments. In the current study, we noted a significant reduction
in OCT thickness after triamcinolone acetonide, in patients
who previously had a limited response to bevacizumab.
Compared to pretriamcinolone macular thickness, the ma-
jority of eyes showed decreased macular edema (90.4%)
after triamcinolone injection. A similar proportion of pa-
tients (90%) maintained or had improved visual acuity, al-
though the acuity improvements were slight.
The design of this study included patients with refractory
responses to bevacizumab. Based on visual acuity measure-
mentsofpatientswhowere included in this study, it is likely that
we have included patientswithmore severe (ischemic) disease.
The reasons for lackofvisual improvement are likelysecondary
to the substantial damage of the photoreceptor cells during the
acute or chronic phase of CRVO or due to chronic macular
Table 1. Characteristics of Patients Before and After Switching to Triamcinolone Acetonide
ID Age
Type
of CRVO
Prior
therapies
Pre-IVTA
BCVA
Post-IVTA
BCVA
Pre-IVTA
CMT
Post-IVTA
CMT
1 69 I B3 CF 3 CF 6 811 233
2 65 I B5 CF 3 CF 4 345 412a
3 54 I B3 20/400 20/300 543 254
4 65 NI B4 20/400 20/100 505 244
5 68 NI B10 20/70 20/50 384 242
6 67 NI B5 CF 7 20/400 537 237
7 59 NI B3 20/200 20/100 305 280
8 61 I B3 20/200 20/200 691 474a
9 69 NI B3 20/200 20/300 544 630a
10 80 NI B3 CF 3 20/400 455 320
11 63 I B5 20/200 20/200 548 241
12 65 NI B4 20/100 20/70 502 269
13 82 I B3 20/200 20/200 492 396
14 82 NI B4 20/80 20/70 539 260
15 70 NI B3 CF 6 20/400 793 317
16 38 NI B3 CF 4 CF 3 603 539a
17 76 NI B6 CF 1 CF 4 300 274
18 65 I B4 20/200 20/200 758 493
19 66 I B3 20/200 20/200 449 265a
20 65 I B6 20/80 20/60 315 239
21 67 NI B4 20/100 20/80 780 268
Mean: 66.4 years 4.18
injections
logMAR
1.19 (20/316)
logMAR
1.04 (20/214)b
533.4mm 327.9 mmc
Clinical features and outcomes for patients who had IVTA after refractory response to multiple intravitreal bevacizumab in CRVO.
aRetreatment.
bP= 0.003.
cP< 0.001.
The ‘‘Prior therapy’’ column lists prior therapies for macular edema before triamcinolone acetonide switch (B, bevacizumab; IVTA,
intravitreal triamcinolone acetonide; CF, counting fingers). Pretriamcinolone acetonide and post-triamcinolone acetonide OCT, and
pretriamcinolone and post-triamcinolone acetonide BCVA columns list best-corrected visual acuities in Snellen notation. All thickness
values were measured using OCT, and numbers listed are in microns, as defined in the Methods section.
BCVA, best-corrected visual acuity; CMT, central macular thickness; CRVO, central retinal vein occlusion; I, ischemic; logMAR,
logarithm of the minimum angle of resolution; NI, non-ischemic; OCT, optical coherence tomography.
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edema.ThelargertrialssuchasStandardCarevs.Corticosteroid
for Retinal Vein Occlusion (SCORE) Study andA Study of the
Efficacy and Safety of Ranibizumab Injection in Patients with
Macular Edema Secondary to Central Retinal Vein Occlusion
(CRUISE) excluded patients with vision worse than 20/400.
These patients likely had ischemic CRVO and were likely to
have a less robust treatment response. IschemicCRVOwas not
excluded in our study. This might be an explanation for the
modest visual improvement seen in our series. Furthermore, in
theCRUISE trial,manypatients experienced rapid reduction in
macular thicknessandrapid improvement invisualacuity.8,12,13
Our study foundbothanatomicandvisualbenefits ina subgroup
of patients who had ischemic disease.
This study is limited by its nonrandomized, noncom-
parative and retrospective nature. The average number of
anti-VEGF injections (4.1) and triamcinolone acetonide in-
jections (1.6) was small compared with the CRUISE and
SCORE studies, respectively, and additional injections may
have enabled greater, although still modest, visual improve-
ment. No significant complications developed in our patients
after treatment with bevacizumab or triamcinolone acetonide,
however, cataract formation and an increase in intraocular
pressure may have occurred with a longer follow-up.
Conclusions
This study evaluated the anatomical and visual effect of
triamcinolone acetonide on eyes previously treated with
IVB. The majority of patients experienced an improvement
in visual acuity, IVTA provided stability of visual acuity in
other patients.
In summary, this study suggests that switching to IVTA
injection may be an effective treatment for patients with
persistent or recurrent macular edema secondary to CRVO
following multiple treatments with bevacizumab. Further
trials may help understand which patients may benefit most
from this treatment modality.
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